ribonolactone: structure given in first source; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
D-ribono-1,4-lactone : A five-membered form of ribonolactone having D-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 111064 |
| CHEMBL ID | 607627 |
| CHEBI ID | 74168 |
| SCHEMBL ID | 625893 |
| MeSH ID | M0159730 |
| Synonym |
|---|
| AC-15682 |
| ribonic acid, gamma-lactone |
| 3327-63-7 |
| d-ribopentono-1,4-lactone |
| d-ribonolactone |
| 5336-08-3 |
| d-ribono-1,4-lactone |
| d-(+)-ribonic gamma-lactone, 97% |
| ribonolactone |
| 93B77B8F-39C4-4159-83A4-A05A3F85E8C5 |
| ribonic acid-1,4-lactone |
| d-(+)-ribonic acid gamma-lactone |
| d-(+)-ribono-1,4-lactone |
| d-(+)-ribonolactone |
| cuokhacjlgprhd-bxxzvtaosa- |
| inchi=1/c5h8o5/c6-1-2-3(7)4(8)5(9)10-2/h2-4,6-8h,1h2/t2-,3-,4-/m1/s1 |
| chebi:74168 , |
| CHEMBL607627 |
| (3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-one |
| ribono-gamma-lactone |
| d-ribonic acid-1,4-lactone |
| d-ribono-1,4-lactone(d-(+)-ribonic acid gamma-lactone) |
| AKOS015955664 |
| d-ribono-gamma-lactone |
| d-ribonolactone (van) |
| ribonic acid, gamma-lactone, d- |
| einecs 226-256-5 |
| 64e63nc231 , |
| unii-64e63nc231 |
| gamma-lactone of ribonic acid |
| (3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)dihydrofuran-2(3h)-one |
| d-ribopentono-1,4-lacton |
| (+)-ribonolactone |
| d-(+)-ribonic acid lactone |
| ribonolactone [inci] |
| CS-M1132 |
| SCHEMBL625893 |
| mfcd00063241 |
| d(+)-ribonic acid gamma-lactone |
| d-(+)-ribonic-g-lactone |
| W-201380 |
| W-200055 |
| J-517584 |
| d-(+)-ribonic acid-gamma-lactone, puriss., >=99.0% (t) |
| delta-(+)-ribonone-1.4-lactone |
| delta-(+)-ribonic acid gamma-lactone |
| d-(+)-ribonic acid g-lactone |
| gamma-lactone-ribonic acid |
| delta-ribonolactone |
| delta-ribono-gamma-lactone |
| delta-ribopentono-1,4-lactone |
| d-(+)-ribonone-1.4-lactone |
| delta-(+)-ribonic acid g-lactone |
| gamma-lactone of ribonate |
| gamma-lactone-ribonate |
| E10111 |
| A851419 |
| d-ribonic acid g-lactone |
| CUOKHACJLGPRHD-BXXZVTAOSA-N |
| Q27144478 |
| AS-46673 |
| HY-76691 |
| delta-ribono-1,4-lactone |
| AMY24722 |
| (3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)-dihydrofuran-2(3h)-one;d-ribono-1,4-lactone |
| DTXSID201347750 |
| (3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-one |
| rel-(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)dihydrofuran-2(3h)-one |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| ribonolactone | |
| butan-4-olide | Any gamma-lactone having the lactone moiety derived from 4-hydroxybutanoic acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID38908 | Inhibitory activity against Arabinose-5-phosphate isomerase at a concentration of 6 mM; Not active. | 1984 | Journal of medicinal chemistry, Jun, Volume: 27, Issue:6 | Inhibition of arabinose 5-phosphate isomerase. An approach to the inhibition of bacterial lipopolysaccharide biosynthesis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.71) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||